Nasdaq's New MVLS Rule: Rethinking Exchange Choice For Micro-Caps

By Driscoll R. Ugarte

The choice between Nasdaq and the New York Stock Exchange (or NYSE American) has traditionally been made once – and rarely revisited. Market perception, investor demographics, analyst coverage, industry concentration, and initial listing eligibility drive the decision at the IPO or uplisting stage; thereafter, exchange selection tends to recede from the boardroom agenda unless a delisting notice forces the issue. That has been especially true in the life sciences and biopharma sector, where Nasdaq’s concentration of specialty analysts, life-sciences-focused institutional capital, and comparable public companies has made it the listing venue of default.

A recent rule change warrants a reassessment of that assumption. On July 22, 2026, the Securities and Exchange Commission (“SEC”) approved Nasdaq’s new continued listing standard, codified as Listing Rules 5450(a)(3) and 5550(a)(6), requiring companies listed on the Nasdaq Global Select Market, Nasdaq Global Market, and Nasdaq Capital Market to maintain a market value of listed securities (“MVLS”) of at least $5 million. The practical effect is to convert exchange selection from a decision made once, at listing, into a matter of continuing governance – one that boards, and particularly those of clinical-stage and pre-commercial life sciences companies, would be well advised to revisit with the same regularity as they do with their cash runway and clinical milestone planning.

The rule is intended to raise the overall quality of the companies listed on Nasdaq, and for most issuers it will have no effect. For a subset of micro-cap issuers (including development-stage life sciences companies without near-term revenue chief among them), however, it introduces a new and distinct delisting risk that merits board attention now, not after a compliance letter arrives.

The Mechanics Of The New Standard

MVLS is calculated as the consolidated closing bid price of a company’s shares multiplied by the total number of shares listed on a national securities exchange. A company whose MVLS remains below $5 million for 30 consecutive business days will receive a staff delisting determination and face immediate suspension from trading. Unlike most continued listing deficiencies (for example, the minimum bid price requirement), there is no cure or compliance period, and the remedy of Nasdaq Hearings Panel review is not as protective as it is in other circumstances. A timely request for review does not automatically stay the suspension. The company’s securities will generally trade in the over-the-counter market while the appeal is pending. For a clinical-stage company, this forecloses what has historically been a viable strategy in the face of a market-value shortfall: continuing to trade on Nasdaq while awaiting the next data readout or regulatory milestone that might restore compliance.

Life Sciences Companies Are Especially Exposed

The new rule is likely to have its greatest impact on companies whose valuations turn on anticipated future value rather than current operating performance. This description fits most of the life sciences and biopharma sectors. Categories facing particular exposure include:

• clinical-stage biotechnology companies (especially those with a single lead asset or small pipeline);
• pharmaceutical companies awaiting FDA or other regulatory approval;
• medical device developers in extended premarket review;
• diagnostics and life sciences tools companies pursuing long, capital-intensive development cycles;
• companies that completed a de-SPAC transaction or small-cap IPO and have since traded well below their offering price; and
• early-stage technology companies and other businesses pursuing extended research and development cycles.

These are, in large part, the same industries that have historically gravitated toward Nasdaq for the reputational and capital markets reasons described above. The consequence is a tension in the rule’s design. The companies most likely to fall below the $5 million threshold are disproportionately the pre-revenue growth companies Nasdaq has long sought to attract. Life sciences issuers bear a particular version of this exposure, with market value in this sector being driven less by current operating performance and more by binary events, coupled with prevailing interest rates, sector forecasts, and the availability of financing. A single disappointing trial result, Complete Response Letter, or delayed advisory committee vote can move market value by 50% or more in a single trading session, rendering a decrease in price below the MVLS threshold an almost ever-present risk rather than a remote contingency, even for a company with a robust pipeline, sound science, and strong balance sheet.

Deficiency Proceedings Rarely Exist In Isolation

Even where compliance is ultimately restored, a cited deficiency imposes practical costs that extend well beyond the exchange rules themselves. Affected companies typically confront:

• increased investor uncertainty;
• greater difficulty raising funds;
• additional scrutiny from counterparties and strategic partners;
• increased legal, accounting, and investor relations expenses; and/or
• management distraction during an already challenging period.

For boards of directors, these indirect costs may ultimately exceed the direct costs of maintaining a listing. Without a cure period under the new rule, boards will have far less runway to manage them. For a clinical stage company, a delisting coming at the same time as a pivotal trial readout or an FDA action may compound the problem, in that management attention that should be devoted to the clinical and regulatory process is instead diverted to exchange compliance. Further, investor uncertainty about listing status can itself affect the company’s ability to raise the financing needed to fund the trial or launch the product.

Is NYSE American The Answer?

NYSE American is not necessarily the answer, which turns on the specific circumstances of the issuer. NYSE American applies a different framework for continued listing compliance, evaluating a combination of financial condition, market capitalization, stockholders’ equity, operating history, public float, and shareholder distribution rather than a single bright-line MVLS threshold. This structure may afford greater flexibility to a company whose valuation is temporarily reduced but whose fundamentals remain sound.

The comparison should not be overstated because NYSE American has been pursuing a substantially similar rule change. In December 2025, NYSE American filed a proposed rule change to amend Section 1003 of the Company Guide to require a minimum $5 million average global market capitalization over a consecutive 30-trading-day period, which is seemingly comparable to Nasdaq’s MVLS standard.

As originally drafted, the NYSE American rule change included immediate suspension and delisting without a compliance plan. However, NYSE American withdrew that specific amendment proposal in March 2026 and refiled substantially the same $5 million standard in a new proposal, which remains pending before the SEC as of the date of this article. The SEC instituted proceedings in June 2026 to determine whether to approve or disapprove it.

If and when that proposal is adopted, the main distinction from the Nasdaq rule is likely to be procedural rather than substantive. As currently drafted, the NYSE American proposal preserves an issuer’s right to appeal a delisting determination to a committee of the exchange’s board. This stands in contrast to Nasdaq’s rule, under which Hearings Panel review does not stay the suspension. NYSE American has cited the Securities Exchange Act’s “fair procedure” requirements in support of retaining the right of appeal. For a life sciences company, that difference may matter considerably. It is the difference between trading on an over-the-counter market for the duration of an appeal and having an opportunity to be heard before suspension takes effect. Boards and counsel should follow the outcome of the current NYSE American proposal closely, as it will determine whether NYSE American ultimately offers a more forgiving continued listing regime than Nasdaq.

None of this reduces Nasdaq’s considerable advantages for most life sciences issuers, including:

• strong brand recognition among growth companies;
• a deep concentration of biotech, pharma, and other life sciences issuers, and the peer-company comparables and specialty analyst coverage that follow them;
• established institutional investor familiarity, including funds focused on life sciences;
• index inclusion (for example, in the Nasdaq Biotechnology Index or relevant Russell indices) and the coverage advantages that follow from it, both of which matter for capital raising in a sector reliant on follow-on and at-the-market offerings; and
• historical preference among venture-backed and clinical-stage companies.

A Recurring (Rather Than One-Time) Board Determination

Exchange selection has traditionally been treated as an event occurring at the time of an IPO, uplisting, or initial listing, rather than a subject of continuing board oversight. That treatment may no longer reflect the risk. Directors of micro-cap and development-stage companies would do well to build a periodic review as part of their annual strategic planning, and more frequently where warranted by trading conditions. This review should cover:

• projected compliance with applicable continued listing standards;
• expected market capitalization trends;
• anticipated financing needs;
• likelihood of a future reverse stock split;
• shareholder composition and analyst coverage;
• investor relations considerations; and
• the relative advantages and disadvantages of each national securities exchange.

If conducted well in advance of any compliance concern, this analysis would allow a board to evaluate its alternatives from a position of strength, rather than within the compressed (and largely cure-free) window that follows a Nasdaq Staff delisting determination.

Practical Considerations Before Any Transfer

A voluntary transfer between exchanges is a strategic decision with operational consequences, not merely a regulatory filing. Management and counsel should evaluate, at minimum:

• continued listing eligibility under the destination exchange;
• applicable listing fees;
• SEC disclosure obligations;
• timing considerations;
• effects on index inclusion;
• analyst coverage and institutional ownership;
• trading liquidity;
• financing strategy; and
• investor communications.

The company also should weigh how a transfer will be perceived. Might it be seen as a proactive strategic decision if undertaken from a position of strength, or as a signal of distress if undertaken only after a prolonged period of compliance concerns? The two narratives are rarely available at the same time, and timing largely determines which one applies.

Looking Ahead

Whether the new MVLS requirement produces a migration of micro-cap companies away from Nasdaq remains to be seen. What is not in doubt is that it has changed the conversation. Exchange selection can no longer be treated as a decision made once at the outset of a company’s life as a public company. It now should be a component of ongoing corporate governance and capital markets strategy, receiving the same periodic attention as financing strategy, executive compensation, and regulatory risk.

For most companies, Nasdaq will remain the preferred venue, and appropriately so. For a smaller set of issuers with prolonged development timelines, structurally volatile valuations, or a history of market capitalization challenges, the rule change warrants a new evaluation of whether another exchange better serves the company’s long-term interests. In either case, boards that address the question deliberately, and before compliance concerns force the issue, will be better positioned than those that do not.

About The Author:

Driscoll R. Ugarte is a Partner at Duane Morris LLP, and Co-Lead of the Life Sciences and Medical Technologies Industry Group. He is a resident in the firm's Boca Raton and Miami offices. With nearly 25 years of experience and leadership in transactions exceeding an estimated $15 billion in aggregate value, he advises on mergers and acquisitions, capital markets, securities regulation and private equity.